

SCHOTT KAISHA brings new portfolio of highly customizable prefillable glass syringes to India

28 December 2018 | News

The new glass syringes work with leading safety and autoinjector devices, meeting market demand for products that can be administered at home for patient comfort.



Leading pharmaceutical packaging company, SCHOTT KAISHA has launched a highly specialized glass syringe portfolio in India, that further minimizes the risk of drug/container interactions for sensitive drugs. As part of its German partner SCHOTT's iQ platform, syriQ BioPure is a hugely customizable glass prefillable staked-needle syringe (PFS) specifically designed to keep sensitive drugs stable over shelf life and shorten time to market while making administration more convenient for patients.

Complex biotech drugs always face a threat of interacting with their container system. These interactions cannot be predicted and can lead to unintentional aggregation or deterioration of the drug which may eventually compromise the total cost of ownership, shelf life of the drug and treatment efficiency.

Rishad Dadachanji, Director, SCHOTT KAISHA shares, "The syriQ BioPure syringes, manufactured in St. Gallen, Switzerland, combine features to ensure stability and safe administration of sensitive drugs. Our clients often work with complex biologicals that require an extremely reliable PFS solution. We are happy with the response that this offering is receiving from our existing and potential clients."

A Quality by Design approach, benchmark manufacturing and quality control processes using breakthrough inspection technology, combined with best-in-class components has established syriQ BioPure as a preferred container solution globally. Its application has proven to be beneficial in achieving:

- Ultra-low tungsten residuals (ICP-MS certificate available)
- Uniform silicon layer
- · Low adhesive residuals
- Low E&L from latest high-quality elastomer formulations

The new glass syringes work with leading safety and autoinjector devices, meeting market demand for products that can be administered at home for patient comfort. Seamless integration into these devices is reached thanks to the syringe's high dimensional accuracy.

About SCHOTT KAISHA:

The company was established in 1991 as a premium manufacturer of pharmaceutical containers made of neutral glass in India under the name KAISHA Manufacturers Pvt. Ltd. In 2008, it started cooperation with the international technology group SCHOTT. The Indo-German joint venture is a leading supplier for the pharmaceutical industry offering a "one stop shop" solution for the entire range of small volume tubular glass parenteral packaging including ampoules, vials, cartridges and sterile prefillable glass syringes.

About SCHOTT AG:

SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of highquality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT strives to play an important part of everyone's life and is committed to innovation and sustainable success. With more than 15,500 employees at production sites and sales offices in 33 countries, the group has a global presence. In the 2016/2017 fiscal year, SCHOTT generated sales of 2.05 billion euros. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.